Latest News
Industry Cooperation
- Publish Date：2026-03-31
NYCU Partners with GWOXI and PODAK to Advance Automated Stem Cell Manufacturing Platform
From left: Chia-Yu Chen, Chairman of PODAK International Corp.; Professor Chi-Ying Huang, Dean of the College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University (NYCU); and Ming-Hsi Chuang, Chairman of Gwo Xi Stem Cell Applied Technology Co., Ltd.
Edited by Chance Lai
______
______
As Taiwan enters the first year of implementing its landmark regenerative medicine legislation in 2026, National Yang Ming Chiao Tung University (NYCU) has taken a leading role in a major industry–academia partnership aimed at accelerating the development of next-generation cell therapies.
On March 27, NYCU signed a memorandum of understanding (MOU) with leading stem cell developer Gwo Xi Stem Cell Applied Technology Co., Ltd. (GWOXI) and electronics distributor-turned-biotech player PODAK International Corp., marking a milestone collaboration to build an advanced automated stem cell manufacturing platform.
Bridging Research and Industry
The partnership underscores strong industry confidence in NYCU’s regenerative medicine research capabilities. Led by the university’s College of Pharmaceutical Sciences, the collaboration integrates:
On March 27, NYCU signed a memorandum of understanding (MOU) with leading stem cell developer Gwo Xi Stem Cell Applied Technology Co., Ltd. (GWOXI) and electronics distributor-turned-biotech player PODAK International Corp., marking a milestone collaboration to build an advanced automated stem cell manufacturing platform.
Bridging Research and Industry
The partnership underscores strong industry confidence in NYCU’s regenerative medicine research capabilities. Led by the university’s College of Pharmaceutical Sciences, the collaboration integrates:
- Clinical-grade stem cell technologies from GWOXI, including U.S. FDA Drug Master File (DMF)-registered adipose-derived stem cells
- Fully automated cell production systems introduced by PODAK from Japan
- NYCU’s strengths in AI-driven drug discovery, data platforms, and translational research
Together, the three parties aim to develop a next-generation automated stem cell processing platform to accelerate the transition from laboratory research to scalable, industrial-level production.
From Lab Innovation to Scalable Manufacturing
The signing ceremony, held at NYCU, coincided with the “2026 Conference on Diagnostics, Therapeutics and Regenerative Medicine,” where international experts witnessed the agreement.
GWOXI Chairman Ming-Hsi Chuang noted that early integration of industry-grade standards is essential for translating academic innovation into real-world applications. By providing FDA DMF-registered clinical-grade stem cells, the company aims to support NYCU as a core R&D platform and help align Taiwan’s regenerative medicine sector with global regulatory pathways.
From Lab Innovation to Scalable Manufacturing
The signing ceremony, held at NYCU, coincided with the “2026 Conference on Diagnostics, Therapeutics and Regenerative Medicine,” where international experts witnessed the agreement.
GWOXI Chairman Ming-Hsi Chuang noted that early integration of industry-grade standards is essential for translating academic innovation into real-world applications. By providing FDA DMF-registered clinical-grade stem cells, the company aims to support NYCU as a core R&D platform and help align Taiwan’s regenerative medicine sector with global regulatory pathways.
PODAK Chairman Chia-Yu Chen highlighted the introduction of Japan’s latest automated cell culture and monitoring system. The platform enables closed, sterile production environments with AI-powered imaging, allowing 24/7 monitoring and standardized large-scale cell expansion—key to ensuring consistency and quality across batches.
NYCU as a Translational Hub
Professor Chi-Ying Huang, Dean of NYCU’s College of Pharmaceutical Sciences, emphasized the university’s role as a bridge between academia and industry.
Leveraging proprietary drug databases and AI-based screening technologies, NYCU can predict drug–target interactions and significantly shorten development timelines. With added industry support, the university will focus on designing next-generation cell therapies and building automated production workflows, while also cultivating talent for Taiwan’s growing biotech sector.
Positioning Taiwan for Global Regenerative Medicine
The collaboration signals a broader shift in Taiwan’s regenerative medicine landscape—from early-stage research to industrial-scale production.
By combining modular manufacturing systems, clinical-grade materials, and automated technologies, the alliance is expected to establish a resilient, scalable supply chain for cell-based therapies. Industry observers note that such a model could not only serve domestic hospitals and clinics, but also position Taiwan to export integrated “cell factory” solutions across the Asia-Pacific region.
As global demand for stem cell therapies continues to grow, NYCU’s leadership in this cross-sector initiative highlights its expanding role in shaping the future of biomedical innovation and industrial translation.
Related Image(s)：
